Pfizer Inc. (NYSE: PFE) is back in the spotlight as of November 30, 2025. Fresh regulatory filings show new institutional buying, analysts are nudging price targets higher, and the company has closed a multibillion‑dollar obesity deal while reshaping its post‑pandemic pipeline.
This article pulls together the most relevant current Pfizer stock news as of November 30, 2025, and explains what it may mean for PFE shareholders.
Key Takeaways
- Share price: Pfizer last traded around $25.7 per share at the close on Friday, November 28, 2025, leaving the stock down roughly 1.8% over the past year and within a 52‑week range of about $20.9–$27.7. [1]
- Valuation: The stock trades on a trailing P/E of ~15 and a forward P/E around 8–9, implying a discount to many big‑pharma peers on earnings‑based metrics. [2]
- Income story: Pfizer’s $0.43 quarterly dividend (payable December 1, 2025) equates to a dividend yield of roughly 6.7% at current prices, placing it among the highest‑yielding names in the S&P 500. [3]
- Current catalysts:
- Fresh institutional accumulation reported today (Estabrook Capital; Schroder Investment Management). [4]
- A completed Metsera acquisition for up to $10 billion, giving Pfizer a foothold in the obesity‑drug race. [5]
- A 54.7% reduction of its BioNTech stake, signaling a pivot away from COVID‑vaccine–driven cash flows toward new growth areas. [6]
- Q3 2025 results with revenue of about $16.7 billion and raised full‑year EPS guidance to $3.00–$3.15. [7]
Pfizer Stock Today: Price, Performance and Valuation
Pfizer’s shares last closed at about $25.74 on November 28, 2025, according to exchange data and several market data providers. [8]
Over the past 12 months, the stock has fallen roughly 1.8%, with a 52‑week trading range of approximately $20.92 to $27.69. That puts PFE closer to the middle of its recent band rather than at the extremes. [9]
On valuation:
- A variety of data sources place Pfizer’s trailing price‑to‑earnings (P/E) ratio around 14–15x, based on the latest twelve months of earnings. [10]
- Forward P/E estimates cluster around 8–9x, depending on provider and exact earnings forecasts. [11]
- Several comparisons show Pfizer trading at a discount to the broader pharmaceuticals industry, where average P/E multiples are in the high‑teens to low‑20s. [12]
In other words, the market is still pricing Pfizer more like a slow‑growing, ex‑COVID cash‑cow than a high‑growth biotech, even as it repivots toward obesity and oncology.
Fresh Today: New Institutional Buying in PFE
The newest headline on November 30, 2025, comes from institutional‑ownership disclosures.
A MarketBeat report published today shows that Estabrook Capital Management increased its Pfizer position by 5.8% in the second quarter, bringing its holdings to 318,925 shares after adding 17,615 shares. [13]
In a separate piece also dated this weekend, Schroder Investment Management Group is reported to have acquired shares of Pfizer, adding another sizeable institutional holder to the cap table. The same report recaps that several Wall Street houses, including Guggenheim, have recently reiterated or upgraded their views on PFE. [14]
Zooming out, a Yahoo Finance analysis notes that about 66% of Pfizer’s shares are held by institutions, making it “a favorite among the big guns” and leaving the stock sensitive to shifts in fund positioning. [15]
For everyday shareholders, this mix of:
- High institutional ownership, and
- Newly disclosed incremental buying
suggests that professional investors remain engaged with the stock, despite its lackluster price performance since the pandemic boom faded.
Analyst Ratings: Modest Upside, but No Consensus Euphoria
Across Wall Street, the message is “cautiously constructive” rather than euphoric.
Different aggregators of analyst forecasts show broadly similar patterns:
- MarketBeat: average 12‑month price target of $28.39 (range roughly $23–$35), implying about 10% upside from current prices. [16]
- TipRanks: average target around $29.17, with a high of $35 and a low of $24, suggesting low‑teens upside. [17]
- StockAnalysis: consensus target near $28.56, again indicating around 11% potential upside. [18]
- ChartMill: mean target of $29.44, about 14% above the current share price. [19]
On the individual‑broker side:
- Guggenheim recently raised its price target from $33 to $35 while maintaining a Buy rating, citing Pfizer’s combination of pipeline potential and dividend income. [20]
- Other firms remain more muted: for example, a recent update referenced on MarketWatch highlighted a “Hold” rating from Wells Fargo. [21]
Put simply: Street models generally see single‑ to low‑double‑digit upside, not a moonshot. The bullish camp leans on obesity, oncology and cost‑cutting; the cautious camp worries about patent expiries, pricing pressure and execution risk.
Q3 2025 Results: Earnings Beat and Higher EPS Guidance
Pfizer’s third‑quarter 2025 results, released on November 4, set much of the tone for how investors are looking at the stock this quarter. [22]
Key numbers:
- Revenue: about $16.7 billion in Q3 2025. [23]
- Adjusted diluted EPS:$0.87, ahead of consensus estimates around $0.79. [24]
- Reported diluted EPS:$0.62, reflecting acquisition‑related charges and restructuring costs. [25]
- Revenue trend: Morningstar notes that Q3 revenue fell about 6% year‑on‑year, as COVID‑related sales continue to taper. [26]
Most importantly for valuation, Pfizer raised and narrowed its 2025 EPS guidance to $3.00–$3.15 per share, while reaffirming revenue guidance of $61–$64 billion. [27]
Management also highlighted:
- Progress toward ~$7.2 billion in net cost savings by 2027, and
- Roughly $7.2 billion of R&D investment in the first nine months of 2025, reinforcing the pivot from COVID cash to pipeline build‑out. [28]
A comprehensive pipeline update, published alongside the earnings materials, details dozens of programs across oncology, inflammation, infectious disease and metabolic disorders. [29]
Metsera Acquisition: Buying a Ticket into the Obesity Drug Race
One of Pfizer’s most consequential strategic moves this year is its successful bid for Metsera, Inc., a clinical‑stage player in obesity and cardiometabolic diseases.
In early November, Reuters reported that Metsera had accepted a sweetened offer from Pfizer worth up to $10 billion, ending a bidding war with Novo Nordisk. Under the final terms, Pfizer is paying a substantial upfront amount per Metsera share plus additional contingent value rights tied to pipeline success. [30]
On November 13, 2025, Pfizer confirmed it had completed the Metsera acquisition, giving the company a dedicated platform in the fast‑growing obesity market. [31]
Metsera’s pipeline includes:
- MET‑097i, a GLP‑1–based obesity candidate designed for once‑monthly injections, and
- MET‑233i, which mimics the hormone amylin and is being studied in combination strategies. [32]
For investors, the Metsera deal matters because:
- Obesity drugs have become one of the most lucrative segments in healthcare.
- Pfizer has lagged Eli Lilly and Novo Nordisk in this space and needed a credible platform to compete.
- The transaction leans heavily on future milestones, aligning much of the consideration with clinical and commercial success rather than paying everything up front. [33]
The flip side: the acquisition adds integration risk and heightens Pfizer’s exposure to political debates around obesity‑drug pricing and reimbursement.
BioNTech Stake Sale: Closing the COVID Chapter
On the same day it confirmed the Metsera acquisition, Pfizer also slashed its stake in BioNTech, its COVID‑vaccine partner.
A Reuters report from November 13 notes that Pfizer reduced its BioNTech holdings by 54.7%, leaving about 1.66 million ADRs, valued at roughly $163.5 million as of September 30. [34]
Pfizer and BioNTech jointly developed Comirnaty, the world’s first authorized mRNA COVID vaccine, which peaked at $37.8 billion in annual sales in 2022 before demand fell sharply. [35]
BioNTech has stressed that the collaboration itself continues, but trimming the stake signals that Pfizer:
- Is no longer relying on BioNTech equity as a major financial lever, and
- Is reallocating capital toward acquisitions like Seagen and Metsera and toward its own in‑house R&D programs. [36]
Complementing this, FierceBiotech reported earlier in November that Pfizer has cut 11 pipeline programs, including some Seagen‑originated assets, a BioNTech‑partnered mRNA vaccine and a mid‑stage MASH (fatty liver disease) combo therapy, as part of a broad pipeline prioritization. [37]
Together, the BioNTech sell‑down and pipeline pruning underline a shift from “lots of shots on goal” toward a more focused set of bets in oncology, obesity and select specialty areas.
High Dividend Yield: 6.7% and a 348‑Quarter Streak
Income investors tend to pay special attention to Pfizer, and the latest dividend news reinforces that reputation.
On October 9, 2025, Pfizer’s board declared a fourth‑quarter 2025 dividend of $0.43 per share, payable on December 1, 2025, to shareholders of record as of November 7. The company emphasized that this will be its 348th consecutive quarterly dividend. [38]
At a recent share price around $25.7, that $0.43 quarterly payout equates to $1.72 annually, or a dividend yield of roughly 6.7%. Google Finance currently lists a yield near 6.68%, putting Pfizer firmly in high‑yield territory among large‑cap U.S. stocks. [39]
A 24/7 Wall St. ranking of the highest‑yielding dividend stocks in the S&P 500 name‑checks Pfizer as one of the index’s top yielders, reflecting both its sizable payout and its compressed share price. [40]
The key question for investors isn’t just the size of the yield but its sustainability. With a forward P/E in the high single digits and management guiding to adjusted EPS comfortably above the annual dividend outlay, the payout currently looks supported by earnings, though any negative surprises in pipeline execution or pricing policy could tighten coverage.
Balance Sheet Watch: $6 Billion in New Notes
On the financing side, Pfizer has been active in the bond market.
According to Investing.com, the company recently completed a $6 billion public notes offering across multiple maturities, adding fresh long‑term debt to its capital structure. [41]
Combined with:
- Large outlays for Seagen (oncology),
- The newly closed Metsera deal, and
- Ongoing share repurchases and dividends,
this issuance underscores how Pfizer is using its still‑strong balance sheet and credit rating to fund a pivot from pandemic windfalls to longer‑duration growth assets.
How the Market Is Pricing Pfizer Now
Price alone doesn’t tell the story; valuation context matters.
Recent data show that:
- Trailing P/E: around 14.9–15.0x. [42]
- Forward P/E: roughly 8–9x expected earnings, depending on the model. [43]
- Price‑to‑book (P/B): about 1.6x, according to several valuation dashboards. [44]
Analysts at Simply Wall St. and other platforms note that Pfizer trades on a P/E meaningfully below both the pharma sector average (around 20x) and the multiples commanded by high‑growth peers like Eli Lilly and Novo Nordisk. [45]
On the other hand, valuation trackers such as GuruFocus and IntellectiaAI categorize Pfizer as sitting in a “fair value” to “slightly undervalued” zone, rather than deeply distressed, once slower revenue growth and patent headwinds are taken into account. [46]
Put differently: the market is not assuming catastrophic decline, but it is also not granting Pfizer a premium multiple for its obesity and oncology optionality—yet.
What to Watch Next for PFE
As of November 30, 2025, the main storylines for Pfizer stock are:
- Metsera integration and obesity data
- Timelines and early‑stage readouts for key assets like MET‑097i and MET‑233i. [47]
- Regulatory and pricing environment
- The recent “drug‑price deal” environment in the U.S., particularly around obesity therapies and Medicare negotiations, will shape how lucrative Metsera and other assets can ultimately be. [48]
- Pipeline reshaping after BioNTech stake cuts and program cancellations
- Whether trimming the BioNTech stake and axing 11 programs sharpens focus and returns, or signals deeper challenges in R&D productivity. [49]
- Execution on guidance
- Delivering on the $3.00–$3.15 EPS guidance and $61–$64 billion revenue range for 2025 will be crucial for justifying even a modest re‑rating. [50]
- Dividend policy and capital allocation
- With a near‑7% yield and a long streak of payouts, any hint of a cut would be material, but sustained cash generation could keep income‑focused investors anchored in the stock. [51]
As always, none of this guarantees future returns. Pfizer’s current setup is a classic value‑versus‑uncertainty trade: low‑teens earnings multiple, high yield, and big strategic bets on obesity and oncology—offset by patent cliffs, political scrutiny on pricing and the need to prove that its new pipeline can replace lost COVID revenue.
References
1. www.investing.com, 2. www.financecharts.com, 3. www.pfizer.com, 4. www.marketbeat.com, 5. www.reuters.com, 6. www.reuters.com, 7. www.businesswire.com, 8. stockanalysis.com, 9. www.investing.com, 10. www.financecharts.com, 11. www.gurufocus.com, 12. simplywall.st, 13. www.marketbeat.com, 14. www.marketbeat.com, 15. finance.yahoo.com, 16. www.marketbeat.com, 17. www.tipranks.com, 18. stockanalysis.com, 19. www.chartmill.com, 20. www.insidermonkey.com, 21. www.marketwatch.com, 22. www.businesswire.com, 23. www.stocktitan.net, 24. www.marketbeat.com, 25. www.stocktitan.net, 26. www.morningstar.com, 27. www.businesswire.com, 28. www.stocktitan.net, 29. www.pfizer.com, 30. www.reuters.com, 31. www.pfizer.com, 32. www.reuters.com, 33. www.reuters.com, 34. www.reuters.com, 35. www.reuters.com, 36. www.reuters.com, 37. www.fiercebiotech.com, 38. www.pfizer.com, 39. www.google.com, 40. 247wallst.com, 41. www.investing.com, 42. www.financecharts.com, 43. www.gurufocus.com, 44. intellectia.ai, 45. simplywall.st, 46. www.gurufocus.com, 47. www.reuters.com, 48. www.reuters.com, 49. www.reuters.com, 50. www.businesswire.com, 51. www.pfizer.com
